More than 100 controlled clinical trials of cannabinoids or whole-plant preparations for various indications have been conducted since 1975.
In Germany, a cannabis extract was approved in 2011 for the treatment of moderate to severe refractory spasticity in multiple sclerosis. It is commonly used off label for the treatment of anorexia, nausea, and neuropathic pain.
The most common side effects of cannabinoids are tiredness and dizziness (in more than 10% of patients), psychological effects, and dry mouth. Tolerance to these side effects nearly always develops within a short time. Withdrawal symptoms are hardly ever a problem in the therapeutic setting.
There is now clear evidence that cannabinoids are useful for the treatment of various medical conditions.